Biotest
- Country
- 🇩🇪Germany
- Ownership
- -
- Established
- 1946-01-01
- Employees
- -
- Market Cap
- $1.4B
- Website
- http://www.biotest.de
Clinical Trials
14
Trial Phases
2 Phases
Drug Approvals
14
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
- Conditions
- Community-acquired Pneumonia
- Interventions
- Drug: Placebo (human albumin 1%)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Biotest
- Target Recruit Count
- 590
- Registration Number
- NCT05722938
- Locations
- 🇺🇸
Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States
🇺🇸University of California San Francisco-Fresno, Fresno, California, United States
🇺🇸UC Davis Health, Sacramento, California, United States
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
- Conditions
- COVID-19PneumoniaCommunity-acquired PneumoniaBacterial PneumoniaRespiratory InfectionViral PneumoniaFungal PneumoniaAcute Respiratory Distress Syndrome
- Interventions
- Drug: Placebo (human albumin 1%)
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Biotest
- Target Recruit Count
- 107
- Registration Number
- NCT05531149
- Locations
- 🇦🇷
Investigational Site #5401, Buenos Aires, Argentina
🇦🇷Investigational Site #5403, Cordoba, Argentina
🇦🇷Investigational Site #5402, Córdoba, Argentina
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Biotest
- Target Recruit Count
- 48
- Registration Number
- NCT05170269
- Locations
- 🇩🇪
4906, Berlin, Germany
🇩🇪4903, Bonn, Germany
🇩🇪4902, Erlangen, Germany
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Biotest
- Target Recruit Count
- 166
- Registration Number
- NCT04576728
- Locations
- 🇧🇷
Investigational site # 5503, Porto Alegre, Brazil
🇧🇷Investigational site # 5502, Santo André, Brazil
🇧🇷Investigational site # 5505, Santo André, Brazil
Adjusted Fibrinogen Replacement Strategy
- Conditions
- Bleeding DisorderHypofibrinogenemia; Acquired
- Interventions
- Biological: FFP/Cryo
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Biotest
- Target Recruit Count
- 222
- Registration Number
- NCT03444324
- Locations
- 🇧🇪
Site 02, Jette, Belgium
🇧🇪Site 01, Leuven, Belgium
🇨🇿Site 54, Brno, Czechia
- Prev
- 1
- 2
- 3
- Next
News
Grifols' Fibrinogen Concentrate BT524 Demonstrates Non-Inferiority in Phase III Trial for Surgical Bleeding
Grifols' fibrinogen concentrate BT524 met its primary endpoint in the Phase III AdFIrst trial, demonstrating non-inferiority to standard of care for treating bleeding in acquired fibrinogen deficiency during major surgery.
Biotest Reports 6% Sales Growth in 2024, FDA Approves Yimmugo for US Market
Biotest AG achieved €726.2 million in sales for 2024, a 6.1% increase driven primarily by strong performance of Intratect and Yimmugo, with EBIT reaching €94.5 million at the upper end of forecast range.
Biotest Submits Fibrinogen Biologics License Application to FDA
Biotest has submitted a Biologics License Application (BLA) to the FDA for its Fibrinogen product, addressing acquired fibrinogen deficiency.
Grifols' Biotest Achieves Phase 3 Success for Fibrinogen Concentrate in Acquired Deficiency Treatment
Biotest's fibrinogen concentrate BT524 met its primary endpoint in the AdFIrst phase 3 trial, demonstrating non-inferiority to standard care in reducing intraoperative blood loss in patients with acquired fibrinogen deficiency.